Blockchain Registration Transaction Record

Oragenics Advances Clinical Trial for Concussion Treatment in New Zealand

Oragenics submits Phase II trial protocol for neurosteroid therapy for mild traumatic brain injury in New Zealand, addressing the need for concussion treatment in the region. Learn more about the company's focus on nasal drug delivery for neurological and infectious diseases.

This news matters as it highlights Oragenics' progress in developing a potential treatment for mild traumatic brain injury, a condition that affects many individuals globally. The submission of the trial protocol signifies a significant step towards addressing the unmet medical need for effective concussion therapies and could potentially impact the way such injuries are managed in the future.